EUVIMEDEUVIMED entdecken
Crossref

Real-World Experience with Avacopan in ANCA-Associated Vasculitis in Portugal

Oliveira Correia, Sofia, Ivo Laranjinha, Estela Nogueira, Cunha, Anita, Catarina Tenazinha, Pinto, Helena, Ferreira, Inês, Fernandes Serodio und 18 weitere

Portuguese Kidney Journal (PKJ) · 03.07.2025

DOI: 10.71749/pkj.103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Portuguese Kidney Journal (PKJ), erschienen am 03.07.2025. Verfasst von Oliveira Correia und 29 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Avacopan, a selective C5a receptor inhibitor, has emerged as a potential corticosteroid-sparing treatment in ANCA-associated vasculitis (AAV). This study aims to evaluate its real-world efficacy and safety in Portuguese patients with active AAV.

Methods

We conducted a multicenter retrospective analysis of 15 adult patients with newly diagnosed or relapsing AAV treated with avacopan across nine academic centers in Portugal. Patients received avacopan 30 mg twice daily in conjunction with standard induction and maintenance therapy. Clinical outcomes, including Birmingham Vasculitis Activity Score (BVAS), prednisolone use, renal function, and adverse events, were assessed at 3, 6 and 12 months.

Results

The median patient age was 65 (interquartile range (IQR): 51.5–75.5), and 60% had de novo AAV. Most patients (93.3%) presented with systemic manifestations, and renal involvement was seen in 60%. Median time to start avacopan was 3.45 months. Prednisolone was discontinued in eight patients, with a median time to cessation of 44 days post-avacopan initiation. Median BVAS at baseline, 3 and 12 months was 23 (13-28.5), 2 (2-4.5) and 0 (0-0), respectively. This consistent downward trend indicates effective disease control (p< 0.05). The median estimated glomerular filtration rate (eGFR) at baseline, 3 and 12 months was 15 (9-31), 38 (20-62) and 48 (36.5-83.5), respectively (n=9, p

Schlagwörter

avacopanANCA-associated vasculitissteroid-sparing therapyreal-world effectivenessBirmingham Vasculitis Activity Scorerenal involvementestimated glomerular filtration ratehepatotoxicitymaintenance monotherapyrelapsing vasculitis

Zitieren

APA

Correia, O., Sofia, Laranjinha, I., Nogueira, E., Cunha, Anita, Tenazinha, C., Pinto, Helena, Ferreira, Inês, Serodio, F., João, Silvano, José, Gonçalves, João, M., Gonçalves, Miguel, …, & Afonso, N. (2025). Real-World Experience with Avacopan in ANCA-Associated Vasculitis in Portugal. Portuguese Kidney Journal (PKJ). https://doi.org/10.71749/pkj.103

Vancouver

Correia O, Sofia, Laranjinha I, Nogueira E, Cunha, Anita, et al. Real-World Experience with Avacopan in ANCA-Associated Vasculitis in Portugal. Portuguese Kidney Journal (PKJ). 2025. doi:10.71749/pkj.103

BibTeX
@article{Correia2025,
  author = {Correia, Oliveira and Sofia and Laranjinha, Ivo and Nogueira, Estela and Cunha and Anita and Tenazinha, Catarina and Pinto and Helena and Ferreira and Inês and Serodio, Fernandes and João and Silvano and José and Gonçalves and João, Maria and Gonçalves and Miguel and Teixeira, Lídia and Teixeira, Vítor Silvestre and Lança, Alice and Inácio, António da Silva and Santos and Clara and Godinho, Iolanda and Vaz, Raquel and Jerónimo, Moura and Teresa and Afonso, Nuno},
  title = {Real-World Experience with Avacopan in ANCA-Associated Vasculitis in Portugal},
  journal = {Portuguese Kidney Journal (PKJ)},
  year = {2025},
  doi = {10.71749/pkj.103}
}
Kostenlos starten →